Prior malignancy within  years before enrollment other than curatively treated cutaneous basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, anal intraepithelial neoplasia, or cutaneous Kaposis sarcoma (KS); participants with prior malignancies must have completed all therapy at least  years before enrollment with no evidence of disease since therapy completion
Participants who had curatively treated invasive malignancies for which all treatments ended within  year prior to the study (with the exception of basal cell or squamous cell carcinoma of the skin)
Prior malignancy requiring systemic therapy within the last  years except for treated basal or squamous cell skin cancer; history of low-grade malignancies with limited potential to progress as determined by the primary investigator may be enrolled
Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ that is unlikely to progress in two years
Basal cell carcinoma of the skin, medulloblastoma, small-cell lung cancer, or hematologic malignancies
Participant with a history of a second cancer diagnosis or reoccurrence <  years from study entry with the exception of a history of squamous or basal cell carcinoma of the skin <  years from study entry will not be excluded from this study
Presence of active nd malignancy requiring treatment; nd malignancies with low activity which do not require treatment (i.e. low grade prostate cancer, basal cell or squamous cell skin cancer) do not constitute exclusions
Patients with concomitant or prior invasive malignancies within the past  years; subjects with limited stage basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the breast, or non-muscle invasive bladder cancer, are eligible as long as they received curative intent therapy
The subject must not have had diagnosis, detection, or treatment of another type of cancer =<  years prior to randomization (except basal or squamous cell carcinoma of the skin that has been definitively treated); questions regarding the inclusion of individual subjects should be directed to the principal investigators, Dr. Isaacs and Dr. Pishvaian
Patients with second malignancies in addition to their lymphoma are not eligible if the second malignancy has required treatment (including maintenance therapy) within the past  years or is not in complete remission; there are two exceptions to this criterion: successfully treated non-metastatic basal cell or squamous cell skin carcinoma
Prior history of malignancy in the past  years with the exception of basal cell and squamous cell carcinoma of the skin; other malignancies that are considered to have a low potential to progress may be enrolled at discretion of principal investigator (PI)
Concomitant malignancies except cutaneous squamous cell carcinoma or basal cell carcinoma
Patients with other active malignancies are ineligible for this study, other than superficial localized skin cancer (basal or squamous cell carcinoma)
The subject has a history of unrelated neoplastic disease, which has been deemed active within thirty-six () months of the screening evaluation, with the exception of the following:\r\n* Non-invasive non-melanoma skin cancer such as superficial basal cell carcinoma or squamous cell carcinoma\r\n* In female subjects: high-grade or low-grade squamous intraepithelial lesions or equivalent cervical lesions\r\n* In male subjects: tumors of the prostate with a combined Gleason score =< 
Prior history of malignancy in the past  years with the exception of basal cell and squamous cell carcinoma of the skin; other malignancies that are considered to have a low potential to progress may be enrolled at discretion of principal investigator (PI)
Concurrent, active malignancies in addition to those being studied (other than cutaneous squamous cell carcinoma or basal cell carcinoma)
Patients with second malignancies in addition to their B-cell malignancy are not eligible if the second malignancy has required treatment (including maintenance therapy) within the past  years or is not in complete remission; there are two exceptions to this criterion: successfully treated non-metastatic basal cell or squamous cell skin carcinoma
No evidence (within  years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin)
Known additional malignancies within the past  years (excluding basal of squamous cell skin cancers, carcinoma in situ (CIS) or localized prostate cancer that has been treated or is being observed)
Active second malignancy within  years prior to enrollment ([in addition to the primary tumor types specified by cohort in Inclusion Criterion Number ], but not including definitively treated superficial melanoma, in-situ, basal or squamous cell carcinoma of the skin).
History of any treatment for cancer within the past two years other than basal cell or squamous cell carcinoma of the skin that has been treated with curative intent
Prior or simultaneous malignancies within the past two years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma)
History of other malignancies within  years prior to day  except for tumors that in the opinion of the investigators have a negligible risk for metastasis or death, such as (but not exclusively) adequately controlled basal cell carcinoma, squamous-cell carcinoma of the skin, or early-stage bladder cancer
Concurrent, active malignancies in addition to those being studied (other than cutaneous squamous cell carcinoma or basal cell carcinoma)
The patient has active cancer in another part of the body, with the exception of superficial cutaneous basal cell or squamous cell carcinomas
Active skin lesion consistent with squamous cell carcinoma at the time of randomization, or a current or prior history of malignant melanoma within  years of study entry.
Patients with other malignancies diagnosed within  years prior to study registration; skin squamous or basal cell carcinoma are exceptions
Prior or simultaneous malignancies within the past two years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma)
Concurrent, active malignancies in addition to that being studied (other than cutaneous squamous cell carcinoma or basal cell carcinoma)
Prior or simultaneous malignancies within the past two years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma)
Presence of active nd malignancy requiring treatment; nd malignancies with low activity which do not require treatment (i.e. low grade prostate cancer, basal cell or squamous cell skin cancer) do not constitute exclusions
Patients must be disease-free of prior invasive malignancies for > years with the exception of basal cell or squamous cell carcinoma of the skin.
Patients are excluded if they have a history of metastatic cancer in addition to melanoma or a history of uncontrolled non-metastatic cancer. Patients with localized squamous cell carcinoma and/or basal cell carcinoma are not excluded.
Active cancer (either concurrent or within the last  years) that requires nonsurgical therapy (e.g. chemotherapy or radiation therapy), with the exception of surgically treated basal or squamous cell carcinoma of the skin, or melanoma in situ
Patients with other active malignancies; however, patients with skin cancers, namely basal cell or squamous cell carcinoma, and malignancies treated with curative intent having no known active disease present for >=  years, may be eligible
Patients with second malignancies in addition to multiple myeloma are not eligible if the second malignancy has required treatment within the past  years or is not in complete remission; there are two exceptions to this criterion: successfully treated non-metastatic basal cell or squamous cell skin carcinoma
No clinical evidence of other malignancies (except basal cell carcinoma)
Participants with another invasive malignancy in the last  years (with the exception of basal cell carcinoma and tumors deemed by the investigator to be of low likelihood for recurrence)
Other malignancies within the past  years except for basal or squamous cell carcinoma of the skin
Patients with concurrent malignancies or malignancies within  years prior to starting study drug (with the exception of tumors common to a single genetic cancer syndrome, i.e. MEN, MEN, von Hippel-Lindau [vHL], tuberous sclerosis complex [TSC] etc., or adequately treated, basal cell skin cancer, squamous cell carcinoma, non-melanoma skin cancer or curatively resected cervical cancer)
Patients with other malignancies diagnosed within  years prior to study registration; skin squamous or basal cell carcinoma are exceptions
Prior or simultaneous malignancies within the past two years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma)
Previous malignant disease (other than target malignancy to be investigated in this trial) within the last  years, with the exception of basal or squamous cell carcinoma of the skin.
Currently active malignancy (other than MF). Prior malignancies are allowed so long as there is no evidence of disease recurrence within the last  years (with the exception of fully excised, non-complicated basal cell carcinoma which can have been active within the prior  years, and certain localized, non-invasive fully excised skin, cervical, breast, prostate or bladder tumors).
Subjects with known history and treatment of malignancy at any site within  years of initial prostate cancer diagnosis; with the exception of basal cell carcinoma (BCC)
History of malignancies other than prostate cancer within the past  years, with the exception of treated basal cell/squamous cell carcinoma of the skin
Other coexisting malignancies or malignancies diagnosed within the last  years, with the exception of basal cell carcinoma, squamous cell carcinoma of the skin, or cervical cancer in situ.
Active cancer, defined as a pathologic diagnosis of or treatment for any cancer, other than basal-cell or squamous-cell carcinoma of the skin, within the past six months; or patients with known recurrent or metastatic disease within the past six months; a pathology report issued at the enrolling site confirming the diagnosis of cancer is required for study enrollment
Invasive malignancy (with the exclusion of basal cell carcinoma or skin squamous cell carcinoma) diagnosed during the last  years before randomization; stage I-II invasive malignancies that were diagnosed more than  years prior to randomization and have been treated curatively are allowed as long as all treatment is finished at least  months prior to randomization
Has active solid tumor malignancies with the exception of localized basal cell or squamous cell skin cancer or the condition under treatment (for example, lymphoma)
Individuals with a history of cancer diagnosis or reoccurrence <  years from study entry may not participate; however, individuals with a history of squamous or basal cell carcinoma of the skin <  years from study entry will not be excluded from this study